SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 16, 2003
SALIX PHARMACEUTICALS, LTD.
(Exact name of registrant as specified in its charter)
| Delaware | 000-23265 | 94-3267443 | ||
(State or other jurisdiction of incorporation) | (Commission file Number) | (IRS Employer ID Number) |
8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina | 27615 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (919) 862-1000
| Item 5. | Other Events and Regulation FD Disclosure |
Salix Pharmaceuticals, Ltd. issued a press release today, July 16, 2003, announcing that it has hired Arthur R. Kamm, Ph.D. as Senior Vice President, Research and Development and Chief Development Officer. A copy of this press release is attached as an exhibit.
| Item 7. | Financial Statements and Exhibits |
(c) Exhibits
| 99.1 | Press Release dated July 16, 2003 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SALIX PHARMACEUTICALS, LTD. | ||||||||
| Date: July 16, 2003 | By: | /s/ ADAM C. DERBYSHIRE | ||||||
Adam C. Derbyshire Senior Vice President and Chief Financial Officer | ||||||||
